Late-breaking data supported the efficacy of icotrokinra, an interleukin-23 inhibitor, for plaque psoriasis. By week 24, 46% of icotrokinra-treated patients achieved IGA 0 and 40% reached PASI 100.

In 2013, itolizumab received approval in India as a safe and effective treatment for plaque psoriasis ... and uncontrolled asthma (EQUIP). Although T eff cells are known to play a central role ...

Plaque psoriasis can also affect the scalp ... Eczema tends to run in families, especially in those prone to allergies and asthma. About half of children diagnosed with eczema also will develop ...

Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, according to a press release.

Get Instant Summarized Text (Gist) Ixekizumab is effective and safe for moderate-to-severe plaque psoriasis, with induction therapy enhancing initial response. A study involving 183 patients ...

(RTTNews) - Johnson & Johnson (JNJ) announced new icotrokinra (JNJ-2113) data from its Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO ...